A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease Clinical Trial

Official title:
A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Status Completed

Clinical Trial Summary

To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Gastroesophageal Reflux
Non-erosive Gastroesophageal Reflux Disease

Clinical Trial Details

NCT number	NCT00165672
Study type	Interventional
Source	Eisai Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	May 2005
Completion date	October 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00165646` - A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease	Phase 3
Completed	`NCT02954848` - Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)	Phase 3
Completed	`NCT01047800` - Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial	N/A
Recruiting	`NCT03811080` - Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease	Phase 3
Completed	`NCT01474369` - Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease	Phase 3